Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 233 | 25 | 206 |
| Samples | 126 | 19 | 106 |
| Peptides | 106 | 15 | 90 |
Function
CDKN1B · Cyclin dependent kinase inhibitor 1B
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 89 amino-acid changes on canonical ENST00000228872 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDKN1B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDKN1B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Endometrial Carcinoma | 2/42 5% | 4/612 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Gastric Carcinoma | 3/74 4% | 7/1809 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 6/2550 0% |
| Melanoma | 1/210 0% | 6/1899 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Head and Neck Carcinoma | 1/85 1% | 4/1574 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 4/1390 0% |
| Colorectal Carcinoma | 1/143 1% | 8/3239 0% |
| Breast Carcinoma | 1/144 1% | 8/3264 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 2/810 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 6/2534 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Pancreatic Carcinoma | 1/89 1% | 2/1611 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 4/2640 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
Mutation Distribution
Where CDKN1B is mutated · all tissues, split by cell line vs tissue
How many mutations in CDKN1B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 233 mutations in CDKN1B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|